Ramucirumab by Eli Lilly and Co for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.

Related Keywords

United States ,Indiana ,America ,Eli Lilly ,Ramucirumab Cyramza ,Globaldata Pharmaceutical Intelligence Center ,Co Lilly ,Metastatic Adenocarcinoma ,Phase Transition Success Rate Model ,North America ,South America ,Middle East ,Pharmaceutical Intelligence ,